Long-term effects of combined B-cell immunomodulation with rituximab and belimumab in severe, refractory systemic lupus erythematosus: 2-year results

BACKGROUND: Anti-CD20 B-cell depletion has not shown superior efficacy to standard immunosuppression in patients with systemic lupus erythematosus (SLE). Besides trial design, potential explanations are incomplete B-cell depletion in relation to substantial surges in B-cell-activating factor (BAFF)....

Descripción completa

Detalles Bibliográficos
Autores principales: Kraaij, Tineke, Arends, Eline J, van Dam, Laura S, Kamerling, Sylvia W A, van Daele, Paul L A, Bredewold, Obbo W, Ray, Argho, Bakker, Jaap A, Scherer, Hans U, Huizinga, Tom J W, Rabelink, Ton J, van Kooten, Cees, Teng, Y K Onno
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8311580/
https://www.ncbi.nlm.nih.gov/pubmed/32591783
http://dx.doi.org/10.1093/ndt/gfaa117

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8311580/
https://www.ncbi.nlm.nih.gov/pubmed/32591783
http://dx.doi.org/10.1093/ndt/gfaa117

Ejemplares similares